Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

February 14, 2020February 14, 2020

Ilixadencel Improves Responses, Extends Survival in Newly-diagnosed Metastatic Kidney Cancer, Trial Results Show

News

Adding Immunicum‘s ilixadencel to standard surgical and medical treatment for newly-diagnosed metastatic renal cell carcinoma — the most common form of kidney cancer — increases patient responses, duration of response, and ... Read more

December 12, 2019January 6, 2020

Gut Bacteria as Means of Boosting Immunotherapy in Advanced Cancers Focus of Clinical Trial

News

Vedanta Bioscience has started a Phase 1/2 trial to test its investigational oral microbiome therapy, VE800, in combination with the immune checkpoint inhibitor Opdivo (nivolumab) as treatment for certain advanced cancers. ... Read more

November 27, 2019November 27, 2019

Surface Oncology Asking to Open Trial of Antibody Therapy for Advanced Solid Cancers

News

Surface Oncology is requesting approval to open a Phase 1/1b clinical trial testing SRF617, an anti-CD39 antibody, either alone or in combination with other cancer immunotherapies in people with advanced solid tumors. ... Read more

October 18, 2019

First Patients Dosed in Phase 1/2 Trial Testing Galinpepimut-S, Keytruda Combo in Advanced Cancers

News

A Phase 1/2 clinical trial assessing the cancer vaccine galinpepimut-S in combination with Keytruda (pembrolizumab) as a treatment for WT-1-positive advanced cancers has started dosing patients, Sellas Life Sciences ... Read more

September 20, 2019September 20, 2019

FDA Fast-tracks Magrolimab for Treatment of Myelodysplastic Syndrome, Acute Myeloid Leukemia

News

Magrolimab, an experimental antibody developed by Forty Seven, was granted fast track designation by the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML) and ... Read more

September 3, 2019

Imfinzi-Tremelimumab Combo Fails to Prolong Overall Survival in Metastatic NSCLC, Phase 3 Trial Shows

News

A combination of tremelimumab plus Imfinzi (durvalumab) is no better than standard chemotherapy at extending the survival of people with metastatic non-small cell lung cancer (NSCLC) with a high ... Read more

August 30, 2019

Pexa-Vec Combo Unlikely to Benefit Advanced Liver Cancer Patients in Phase 3 Trial, Monitoring Group Says

News

Adding the cancer vaccine Pexa-Vec to Nexavar (sorafenib), a standard of care, is not likely to improve overall survival of patients with advanced liver cancer, an interim analysis by the ... Read more

August 20, 2019

INmune Bio Shares Early Results of Phase 1 Trial of INB03 for Advanced Cancer Treatment

News

INmune Bio’s therapy candidate INB03 is well-tolerated and has shown signs of activity in patients with advanced cancers, according to preliminary findings from a Phase 1 clinical trial. The early ... Read more

August 9, 2019

Upcoming Phase 2 Trial Will Test Opdivo-MTG201 Combo for Malignant Pleural Mesothelioma

News

An upcoming Phase 2 trial will explore the safety and effectiveness of a combo therapy — Opdivo (nivolumab) and MTG201 – for the treatment of malignant pleural mesothelioma. The ... Read more

July 30, 2019August 26, 2019

ONCOS-102, Keytruda Combo May Reduce Tumor Size in Treatment-resistant Melanoma, Early Trial Data Show

News

Melanoma patients who become resistant to immune checkpoint inhibitors may regain susceptibility to such treatments after receiving Targovax‘s immune activator ONCOS-102, early clinical trial findings suggest. The trial is ... Read more

Pin It on Pinterest